Therapeutic potential of adenosine receptor modulators in cancer treatment
Open Access
- 16 June 2025
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (26) , 20418-20445
Abstract
All human cells contain the universal autocoid adenosine, which interacts with four types of G protein-coupled receptors (GPCRs), namely A1, A2A, A2B, and A3 adenosine receptors (ARs). Among these receptors, A2A and A2B ARs activate adenylate cyclase, while A1 and A3 ARs suppress the adenylate cyclase activity. Adenosine-receptor interactions play a crucial role in cancer biology by modulating the immune microenvironment, which tumors exploit to create immunosuppression that promotes their growth and metastasis. When the A2A AR is activated on natural killer (NK) cells and T cells, it reduces their ability to carry out cytotoxic functions. This activation also encourages the formation of immune-suppressing cell types, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), further weakening the immune response. Targeting adenosine receptors, particularly the A2A subtype, represents a promising therapeutic strategy. By antagonizing these receptors, it may be possible to restore T cell function, helping the body to recognize and attack cancer cells more effectively. Despite recent advancements in the discovery of novel, targeted anticancer agents, these treatments have shown limited effectiveness against metastatic tumours, complicating cancer management. Moreover, developing adenosine receptor agonists or antagonists with high target selectivity and potency remains a significant challenge, as the widespread distribution of adenosine receptors throughout the body raises concerns about off-target effects and reduced therapeutic efficacy. In order to improve outcomes for patients with advanced cancer, researchers are actively investigating safer and more efficient chemotherapy substitutes. However, drugs that activate A3 adenosine receptors and block A2A receptors are being explored as a novel approach for cancer treatment. Monoclonal antibodies and small-molecule inhibitors targeting the CD39/CD73/A2A AR axis are also being tested in clinical trials, both as standalone treatments and in combination with anti-PD-1/PD-L1 immunotherapies. This review primarily focuses on the signaling pathways and the therapeutic potential of various adenosine receptor agonists and antagonists across various cancer types, highlighting their ongoing evaluation in preclinical and clinical trials, both as monotherapies and in rational combination with immunotherapy, chemotherapy, or targeted therapies, potentially leading to the development of advanced treatments that could aid in tumor suppression.Keywords
This publication has 234 references indexed in Scilit:
- [1,2,4]Triazolo[1,5‐c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell LinesChemMedChem, 2023
- Role of adenosine signaling in the pathogenesis of breast cancerJournal of Cellular Physiology, 2017
- Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancerJournal of Cellular Physiology, 2017
- History and Perspectives of A2AAdenosine Receptor Antagonists as Potential Therapeutic AgentsMedicinal Research Reviews, 2015
- Resveratrol 3‐O‐d‐glucuronide and resveratrol 4′‐O‐d‐glucuronide inhibit colon cancer cell growth: Evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrestMolecular Nutrition & Food Research, 2013
- Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell deathMolecular Nutrition & Food Research, 2013
- CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liverJournal of Cellular Physiology, 2010
- Expression and function of A2B adenosine receptors in the U87MG tumor cellsDrug Development Research, 2003
- Adenosine acts through an A3 receptor to prevent the induction of murine anti‐CD3‐activated killer T cellsInternational Journal of Cancer, 2002
- Adenosine as a possible inhibitor of killer T‐cell activation in the microenvironment of solid tumoursInternational Journal of Cancer, 1994